Skip to main content
Clinical Trials/NCT04077749
NCT04077749
Withdrawn
Early Phase 1

A Randomized Double Blinded Study of Probiotic Bladder Instillation for Prevention of Catheter Associated UTIs in Chronically Catheterized Patients

Lahey Clinic0 sitesApril 1, 2021

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Urinary Tract Infections
Sponsor
Lahey Clinic
Primary Endpoint
Bladder colonization with Lactobacillus
Status
Withdrawn
Last Updated
4 years ago

Overview

Brief Summary

The proposed study is a randomized, placebo-controlled clinical trial to test the efficacy of an oral Lactobacillus product dissolved in sterile saline and instilled into the urinary bladder in an attempt to colonize the urinary bladder as well as prevent UTIs.

Detailed Description

Patients who use a chronic indwelling urinary catheter to drain their bladder will be randomized to receive intravesical instillations of a Lactobacillus solution or sterile saline at the time of a scheduled monthly catheter exchange. Bacterial colonization and frequency of urinary tract infections will be compared between the two groups. The Lactobacillus solution will be derived from the combination of Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus and manufactured by CHR-Hansen of Denmark (phone: +45 45747474; email: info@chr-hansen.com). The contents of the capsules will be dissolved in 50 mL of normal saline at room temperature within one hour prior to administration and left indwelling in the patient's urinary bladder for 30 minutes.

Registry
clinicaltrials.gov
Start Date
April 1, 2021
End Date
September 15, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years of age
  • Chronic indwelling urethral catheter or supra-pubic tube for \>6 months
  • Prior symptomatic UTI while catheter in place

Exclusion Criteria

  • Immunosuppressed (HIV, transplant immunosuppression, uncontrolled diabetes)
  • Active infection (may be considered after treatment of active infection)
  • Prior urosepsis requiring ICU admission
  • Significant gross hematuria resulting from catheter exchanges
  • Supravesical urinary diversion
  • Upper urinary tract anatomical abnormality
  • Obstructing urolithiasis
  • Ongoing antibiotic therapy for non-urological infection
  • Indwelling nephrostomy tube or ureteral stent
  • Radiation cystitis

Outcomes

Primary Outcomes

Bladder colonization with Lactobacillus

Time Frame: 6 months

Percent of patients with urine cultures positive for lactobacilli species after 6 months.

Similar Trials